SCHEMBL24477294

SCHEMBL24477294

Cc1cc(C)n2nc(C)c(C(=O)NCc3ccc(-c4cnco4)cc3C)c2n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.39
KCNJ1 P48048 1/20 0.38
KDM4E B2RXH2 7/20 0.38
ALDH1A1 P00352 7/20 0.38
HPGD P15428 6/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP1A1 P04798 1/20 0.37
KMT2A Q03164 2/20 0.36
KCNQ3 O43525 2/20 0.35
KCNQ2 O43526 2/20 0.35
MAPK8 P45983 1/20 0.35
POLB P06746 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
BTK Q06187 5/20 0.34
TP53 P04637 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24477303 0.85 ALDH1A1 (0.56) KDM4EALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL24477304 0.77 ALDH1A1 (0.59) KDM4EALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL24477292 0.76 MAPT (0.36) KDM4EALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL24477307 0.76 ALDH1A1 (0.44) KCNJ1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24477291 0.76 TYK2 (0.42) KCNJ1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24477293 0.74 APOBEC3A (0.50) APOBEC3AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL24477486 0.74 GSK3A (0.48) KCNJ1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24477302 0.70 MAPT (0.36) KDM4EALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL24477481 0.68 TYK2 (0.42) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL19629099 0.67 LMNA (0.54) KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169652-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2022-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169652-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS PARK7, PNP, GAA APOBEC3A 320/4885KCNJ1 2105/4885KDM4E 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.